Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS Toward Phase 2 Trials

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward Phase 2 clinical trials after demonstrating a favorable safety profile in Phase 1 studies. The company reported that Phase 1 studies in healthy volunteers showed the therapy was generally well tolerated, supporting progression into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, which paves the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.

LUCID-MS is designed to target demyelination and protect or restore myelin integrity, addressing the underlying mechanisms of multiple sclerosis. Unlike existing therapies that primarily focus on immune modulation, LUCID-MS aims to directly combat myelin loss and neurodegeneration, potentially offering a differentiated, first-in-class approach. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists, as highlighted in a recent article featuring the company (https://ibn.fm/AUhNl).

The importance of this advancement lies in the unmet medical need for treatments that can repair myelin damage and slow or reverse disease progression in multiple sclerosis. Current disease-modifying therapies reduce relapse rates but do not effectively address neurodegeneration or promote remyelination. If LUCID-MS proves successful in Phase 2 trials, it could represent a significant breakthrough for patients suffering from this chronic, debilitating condition that affects approximately 2.8 million people worldwide.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also retains an ownership stake in Unbuzzd Wellness Inc., which markets unbuzzd, an over-the-counter product, and is entitled to royalty payments from sales.

The company’s forward-looking statements emphasize the risks and uncertainties inherent in drug development, including the need for additional funding, regulatory approvals, and successful clinical outcomes. As Quantum BioPharma moves LUCID-MS into Phase 2, the medical community will be watching closely for evidence of efficacy in patients. The company’s newsroom provides updates on its latest developments (https://ibn.fm/QNTM).